Related Experiment Video

Updated: Jul 4, 2026

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus
09:53

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

Published on: August 25, 2017

Targeting mTOR in HIV-Negative Classic Kaposi's Sarcoma

Ofer Merimsky1, Irina Jiveliouk, Ronit Sagi-Eisenberg

  • 1Unit of Bone and Soft Tissue Oncology, Division of Oncology, Tel-Aviv Sourasky Medical Center, 6 Weitzman Street, Tel-Aviv 64239, Israel.

Sarcoma
|May 30, 2008
PubMed

Insights

Rapamycin, an mTOR inhibitor, effectively treated a patient with HIV-negative classic Kaposi's sarcoma. This suggests the mTOR pathway is crucial in Kaposi's sarcoma development and rapamycin shows therapeutic potential.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Classic Kaposi's sarcoma (KS) is a complex malignancy.
  • The role of the mechanistic target of rapamycin (mTOR) pathway in KS tumorigenesis requires further elucidation.
  • Targeting the mTOR pathway represents a potential therapeutic strategy for KS.

Observation:

  • A 66-year-old female patient with HIV-negative classic Kaposi's sarcoma was treated with rapamycin.
  • Positron Emission Tomography-Computed Tomography (PET-CT) was utilized to document the patient's response.
  • The patient exhibited a significant clinical response to the rapamycin therapy.

Findings:

  • The patient's Kaposi's sarcoma showed a positive response to rapamycin, an inhibitor of the mTOR pathway.
  • PET-CT imaging confirmed the reduction in tumor burden and metabolic activity.
  • This case provides evidence for the involvement of the mTOR pathway in the development of Kaposi's sarcoma.

Implications:

  • The mechanistic target of rapamycin (mTOR) pathway is implicated in the pathogenesis of Kaposi's sarcoma.
  • Rapamycin demonstrates potential therapeutic activity against HIV-negative classic Kaposi's sarcoma.
  • Further clinical trials are warranted to investigate rapamycin as a treatment option for Kaposi's sarcoma.

More Related Videos

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)07:02

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus (KSHV)

Published on: September 14, 2010

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...